study the low sodium P<0.05 (between SBP: -13.0mmHg (1989b) arm were allocated groups) (CI: -25.92, -0.08) to one of two Crossover study DBP: -1.80mmHg cross-over arms: design: (CI: -8.62, 5.02) 1. 80mmol sodium Normal sodium Crossover design tablets/day with period: 198.8 + study: restricted sodium 37.4 mmol/24hr diet continued SBP: -9.70mmHg Low sodium period: (CI: -25.78, 6.38) 2. placebo with 122.6 + restricted sodium (from WHO) diet continued DBP: Change data not provided in WHO, see spreadsheet for means Key features for bias assessment of randomised trials Citation Method of Allocation Blinding Loss to follow-up Use of Ceasing study Reporting Funding randomisation concealment early for all source where benefit outcome required results Dodson et Both study Both study Parallel design study Parallel design Parallel design No (low risk) Yes (low Not stated al. (1989) designs: designs: study: study: risk) (unclear risk) (company
study (1989b) the low sodium arm were allocated to one of two cross-over arms: 1. 80mmol sodium tablets/day with restricted sodium diet continued 2. placebo with restricted sodium diet continued P<0.05 (between groups) Crossover study design: Normal sodium period: 198.8 + 37.4 mmol/24hr Low sodium period: 122.6 + SBP: -13.0mmHg (CI: -25.92, -0.08) DBP: -1.80mmHg (CI: -8.62, 5.02) Crossover design study: SBP: -9.70mmHg (CI: -25.78, 6.38) (from WHO) DBP: Change data not provided in WHO, see spreadsheet for means Key features for bias assessment of randomised trials Citation Method of randomisation Allocation concealment Blinding Loss to follow-up Use of where required Ceasing study early for benefit Reporting all outcome results Funding source Dodson et al. (1989) Both study designs: Both study designs: Parallel design study Parallel design study: Parallel design study: No (low risk) Yes (low risk) Not stated (unclear risk) (company
Sodium%20Supporting%20Document%201%20%20Systematic%20Literature%20Review.docx